Physician profile
Allison L Thomas
NPI 1861669715
$3,801.07
in general payments reported to CMS, 2019-2025
34 companies · $544 in 2025
The $544 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $1,779 · 2023: $567 · 2024: $594 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.61 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,307.27 | 2022 | |
| Pfizer INC. | $485.59 | 2022-2025 | |
| Abbvie INC. | $376.54 | 2021-2025 | |
| Novo Nordisk INC | $297.49 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.87 | 2022-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $147.36 | 2023 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.07 | 2021-2025 | Jardiance, Jascayd |
| Amgen INC. | $135.73 | 2021-2025 | Evenity, Krystexxa, Prolia |
| Glaxosmithkline, LLC. | $89.49 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $73.33 | 2021-2024 | Fruzaqla, Alunbrig |
| Madrigal Pharmaceuticals | $62.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Astrazeneca Pharmaceuticals LP | $45.09 | 2021-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $39.04 | 2021-2022 | |
| Lilly USA, LLC | $38.12 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $29.32 | 2025 | Ultomiris |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $28.21 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Mayne Pharma Commercial LLC | $27.46 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $25.51 | 2021 | |
| Corcept Therapeutics | $23.88 | 2025 | Korlym |
| Aveo Pharmaceuticals, INC. | $22.99 | 2024 | |
| Scilex Pharmaceuticals INC. | $22.00 | 2024 | |
| Amarin Pharma, INC. | $21.03 | 2022 | |
| Exact Sciences Corporation | $19.45 | 2025 | The Cologuard Plus Collection Kit |
| Grifols USA, LLC | $18.25 | 2023 | Prolastin-C Liquid |
| Pharmacyclics LLC, An Abbvie Company | $17.28 | 2022 | |
| Tersera Therapeutics LLC | $16.91 | 2024 | Xermelo |
| Otsuka America Pharmaceutical, INC. | $15.70 | 2023 | Rexulti |
| Kyowa Kirin, INC. | $15.11 | 2023 | Poteligeo |
| Janssen Pharmaceuticals, INC | $14.24 | 2021 | |
| Antares Pharma, INC. | $14.22 | 2025 | Xyosted |
| Acella Pharmaceuticals, LLC | $13.87 | 2023 | NP Thyroid 60 |
| Idorsia Pharmaceuticals US INC | $13.86 | 2023 | Quviviq |
| Alnylam Pharmaceuticals INC. | $13.55 | 2022 | |
| Merck Sharp & Dohme LLC | $13.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.